Evaluation of Inflammatory Markers and Clinical Outcomes in COVID-19 Patients with Concurrent <i>Clostridioides difficile</i> Infection: A Comparative Cohort Analysis by Flavia Ignuta, Adrian Vlad, Teodor Cerbulescu, Stana Loredana, Felix Bratosin, Ovidiu Rosca, Lavinia Stelea, Daciana Nistor

“…Future studies should expand on these findings to optimize care and guide therapeutic strategies.…”
Get full text

Neuroprotective role of epigallocatechin-3-gallate, albeginin and melanoxetin in alzheimer's disease by Arif Malik, Mehreen Hassan, Sulayman Waquar, Muhammad Wasim, Anam Naz, Faryal M. Awan, Muhammad T. Khan, Ali I. Khawaja, Sumera Zaib, Jamshed Iqbal, Ayesha Zahid, Marvi Marvi, Javeid Iqbal, Heng Wang, Dong-Qing Wei

“…Conclusion: This is the first comprehensive study on the therapeutic role of EGCG, albeginin, and melanoxetin against AD. …”
Get full text

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy by Tian He, Bin Xu, Lu-Na Wang, Zi-Yi Wang, Huan-Chen Shi, Cheng-Jie Zhong, Xiao-Dong Zhu, Ying-Hao Shen, Jian Zhou, Jia Fan, Hui-Chuan Sun, Bo Hu, Cheng Huang

“…Conclusion SII is a promising predictor of both therapeutic efficacy and prognosis in HCC patients undergoing immune-based treatments. …”
Get full text

Unveiling the role of ASPP1 in cancer progression: pan-cancer bioinformatics and experimental validation in colorectal cancer by Keyuan Xiao, Xiang Li, Ihsan Ullah, Wenqing Hu, Kaiqiang Wang, Fan Yang, Chengyu Yang, Chunqi Feng, Liang Zong, Xinghua Li

“…The findings support ASPP1’s involvement in tumor biology, particularly regarding cell proliferation and metastatic potential, establishing a foundation for further investigation into its therapeutic relevance.…”
Get full text

Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer by Xiang Pan, Kailai Chen, Wei Gao, Meiqi Xu, Fanlong Meng, Mengyuan Wu, Zi Qi Wang, Yun Qi Li, Wanhai Xu, Manjie Zhang, Yakun Luo

“…Additionally, we developed an efficient and safe PTT strategy based on a nanodelivery system that codelivers circBNC2 and DTX, highlighting its potential as a novel therapeutic approach for mCRPC.…”
Get full text

CT45A1‐mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell‐in‐cell structure, potentiating the progression of microsatellite... by Hao‐Wei Teng, Hsiang‐Yueh Huang, Chun‐Chi Lin, Yuh‐Ching Twu, Wen‐Hao Yang, Wen‐Chun Lin, Hsin‐Yi Lan, Yen‐Yu Lin, Wei‐Lun Hwang

“…However, CT45A1‐expressing MSI‐H CRC cells, but not MSS CRC cells, showed higher resistance to natural killer (NK) cell cytotoxicity and served as outer cells in homotypic CIC structures, preventing exogenous or therapeutic antibody access to inner CRC cells. Inactivating RHO‐ROCK/MLCK‐MLC2 signaling with small‐molecule inhibitors or short‐hairpin RNAs (shRNAs) targeting myosin light chain kinase (MYLK) abolished NK cell resistance and reduced the outer cell fate of CT45A1‐expressing MSI‐H CRC cells. …”
Get full text

Dual role of ramR mutation in enhancing immune activation and elevating eravacycline resistance in Klebsiella pneumoniae by Wei Yu, Peiyao Jia, Xiaobing Chu, Shengjie Li, Xinmiao Jia, Ying Zhu, Xiaoyu Liu, Yingchun Xu, Qiwen Yang

“…To determine how specific mutations in ramR influence eravacycline (ERV) resistance and their impact on the immune activation capabilities of K. pneumoniae, thereby highlighting potential targets for therapeutic intervention, we performed genetic sequencing to identify mutations in ramR. …”
Get full text

Comparative analysis of dominant gut microbiota in Inflammatory Bowel Disease patients and healthy individuals: A case-control study by Alireza Ahmadi, Ebrahim Kouhsari, Shabnam Razavi, Nima Mohamadzadeh, Sima Besharat, Mohammad Ali Vakili, Taghi Amiriani

“…Further research is needed to translate these insights into targeted therapeutic strategies and to explore their effectiveness in clinical settings.…”
Get full text

Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS by Francesco Bertoldo, Cristina Eller-Vainicher, Vittorio Fusco, Rodolfo Mauceri, Jessica Pepe, Alberto Bedogni, Andrea Palermo, Umberto Romeo, Giuseppe Guglielmi, Giuseppina Campisi

“…., CTIBL and its management, pharmacology and pharmacodynamics of BMAs, definition and diagnosis of MRONJ), developed a joint report on the following five issues: a) prevention and dental management in cancer patients candidates to LD-BMAs, or under LD-BMAs; b) prophylactic drug holiday; c) MRONJ treatment; d) LD-BMAs therapeutic drug holiday; and e) restart of LD-BMA treatment after successful healing of MRONJ.Finally, ten key questions with answers were prepared and placed at the end of the document. …”
Get full text

The mechanism of tea tree oil regulating the damage of hydrogen sulfide to spleen and intestine of chicken by Yachao Wang, Yilei Liang, Yan Huang, Wei wang, Xiaoyan Long, Li Jiang, Tingting Cheng, Jinfeng Du, Xuegang Luo

“…The study aimed to assess the therapeutic impact of tea tree oil (TTO) on H2S-induced spleen and intestinal injuries in chickens. …”
Get full text

Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world compar... by Rohan Khera, Yuan Lu, Harlan M Krumholz, Martijn J Schuemie, Ruijun Chen, George Hripcsak, Marc A Suchard, Patrick B Ryan, Anna Ostropolets

“…Introduction Therapeutic options for type 2 diabetes mellitus (T2DM) have expanded over the last decade with the emergence of cardioprotective novel agents, but without such data for older drugs, leaving a critical gap in our understanding of the relative effects of T2DM agents on cardiovascular risk.Methods and analysis The large-scale evidence generations across a network of databases for T2DM (LEGEND-T2DM) initiative is a series of systematic, large-scale, multinational, real-world comparative cardiovascular effectiveness and safety studies of all four major second-line anti-hyperglycaemic agents, including sodium–glucose co-transporter-2 inhibitor, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas. …”
Get full text

Skullcapflavone II suppresses TGF-β-induced corneal epithelial mesenchymal transition in vitro by Meng-Xi Li, Zhen Zhang, Yue Zhang, Fan-Ru Zhao, Yu-Fan Li, Yu-Fei Dang, Yang-Yang Yue, Li Li

“…Thus, SCF-II represents a candidate putative therapeutic agent in corneal fibrotic diseases.…”
Get full text

CircHipk3 serves a dual role in macrophage pyroptosis by promoting NLRP3 transcription and inhibition of autophagy to induce abdominal aortic aneurysm formation by Donghua Cai, Chuling Li, Yingyuan Zhang, Sisi He, Yihai Guo, Wangjun Liao, Yulin Liao, Jianping Bin, Xiang He

“…Targeting CircHipk3 may offer a novel therapeutic strategy to prevent pyroptosis and AAA development, positioning it as a potential treatment target.…”
Get full text

Single-cell transcriptomics reveals the heterogeneity and function of mast cells in human ccRCC by Xiyu Song, Xiyu Song, Xiyu Song, Jianhua Jiao, Jianhua Jiao, Jiayang Qin, Wei Zhang, Weijun Qin, Weijun Qin, Shuaijun Ma, Shuaijun Ma

“…Although the proportion of activated MCs was not significantly altered in ccRCC tissues compared with normal tissues, this finding highlights a shift in the MC phenotype from CTSGhighMCs to more activated VEGFA+MCs, providing a potential therapeutic target for inhibiting ccRCC progression.…”
Get full text

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression by Weijuan Zhang, Jiejie Xu, Hailong Liu, Yu Zhu, Zewei Wang, Han Zeng, Zhaopei Liu, Yuan Chang, Le Xu, Kaifeng Jin, Jingtong Xu, Xiaohe Su, Yawei Ding, Lingkai Zhang, Jiaxing Sun, Yuzhen Wu

“…We assessed the correlation between MDM2 status and clinical outcomes, therapeutic efficacy, and immunological characteristics by immunohistochemical analysis and targeted sequencing. …”
Get full text

CMPK2 promotes NLRP3 inflammasome activation via mtDNA‐STING pathway in house dust mite‐induced allergic rhinitis by YaoMing Zheng, YaDong Xie, JiaYing Li, YuJie Cao, Min Li, Qing Cao, MiaoMiao Han, HongFei Lou, YiLai Shu, Hui Xiao, HuaBin Li

“…Conclusions Our results suggest that HDM promotes the activation of NLRP3 inflammasome through the up‐regulation of CMPK2 and ensuing mtDNA‐STING signalling pathway, hence revealing additional therapeutic target for AR. Key points Cytidine/uridine monophosphate kinase 2 (CMPK2) expression is up‐regulated in the nasal mucosa of patients and mice with allergic rhinitis (AR). …”
Get full text

Early diagnosis and the effect of treatment compliance on the prognosis and progression of glaucomatous optic neuropathy by S.V. Diordiychuk, A.V. Kuroyedov, N.E. Fomin, O.V. Gapon’ko, V.V. Gorodnichiy, I.V. Kondrakova, N.M. Sol’nov

“…These factors include early diagnosis, accessible and effective screening system, rational management strategy that implies the drug change to prevent the reduction in therapeutic effect, and patient adherence to treatment that involves explaining the causes and characteristics of disease cours e, potential complications with recommendation noncompliance, and a professional work a doctor with a patient.…”
Get full text

Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design. by Rachel S Gross, Tanayott Thaweethai, Erika B Rosenzweig, James Chan, Lori B Chibnik, Mine S Cicek, Amy J Elliott, Valerie J Flaherman, Andrea S Foulkes, Margot Gage Witvliet, Richard Gallagher, Maria Laura Gennaro, Terry L Jernigan, Elizabeth W Karlson, Stuart D Katz, Patricia A Kinser, Lawrence C Kleinman, Michelle F Lamendola-Essel, Joshua D Milner, Sindhu Mohandas, Praveen C Mudumbi, Jane W Newburger, Kyung E Rhee, Amy L Salisbury, Jessica N Snowden, Cheryl R Stein, Melissa S Stockwell, Kelan G Tantisira, Moriah E Thomason, Dongngan T Truong, David Warburton, John C Wood, Shifa Ahmed, Almary Akerlundh, Akram N Alshawabkeh, Brett R Anderson, Judy L Aschner, Andrew M Atz, Robin L Aupperle, Fiona C Baker, Venkataraman Balaraman, Dithi Banerjee, Deanna M Barch, Arielle Baskin-Sommers, Sultana Bhuiyan, Marie-Abele C Bind, Amanda L Bogie, Tamara Bradford, Natalie C Buchbinder, Elliott Bueler, Hülya Bükülmez, B J Casey, Linda Chang, Maryanne Chrisant, Duncan B Clark, Rebecca G Clifton, Katharine N Clouser, Lesley Cottrell, Kelly Cowan, Viren D'Sa, Mirella Dapretto, Soham Dasgupta, Walter Dehority, Audrey Dionne, Kirsten B Dummer, Matthew D Elias, Shari Esquenazi-Karonika, Danielle N Evans, E Vincent S Faustino, Alexander G Fiks, Daniel Forsha, John J Foxe, Naomi P Friedman, Greta Fry, Sunanda Gaur, Dylan G Gee, Kevin M Gray, Stephanie Handler, Ashraf S Harahsheh, Keren Hasbani, Andrew C Heath, Camden Hebson, Mary M Heitzeg, Christina M Hester, Sophia Hill, Laura Hobart-Porter, Travis K F Hong, Carol R Horowitz, Daniel S Hsia, Matthew Huentelman, Kathy D Hummel, Katherine Irby, Joanna Jacobus, Vanessa L Jacoby, Pei-Ni Jone, David C Kaelber, Tyler J Kasmarcak, Matthew J Kluko, Jessica S Kosut, Angela R Laird, Jeremy Landeo-Gutierrez, Sean M Lang, Christine L Larson, Peter Paul C Lim, Krista M Lisdahl, Brian W McCrindle, Russell J McCulloh, Kimberly McHugh, Alan L Mendelsohn, Torri D Metz, Julie Miller, Elizabeth C Mitchell, Lerraughn M Morgan, Eva M Müller-Oehring, Erica R Nahin, Michael C Neale, Manette Ness-Cochinwala, Sheila M Nolan, Carlos R Oliveira, Onyekachukwu Osakwe, Matthew E Oster, R Mark Payne, Michael A Portman, Hengameh Raissy, Isabelle G Randall, Suchitra Rao, Harrison T Reeder, Johana M Rosas, Mark W Russell, Arash A Sabati, Yamuna Sanil, Alice I Sato, Michael S Schechter, Rangaraj Selvarangan, S Kristen Sexson Tejtel, Divya Shakti, Kavita Sharma, Lindsay M Squeglia, Shubika Srivastava, Michelle D Stevenson, Jacqueline Szmuszkovicz, Maria M Talavera-Barber, Ronald J Teufel, Deepika Thacker, Felicia Trachtenberg, Mmekom M Udosen, Megan R Warner, Sara E Watson, Alan Werzberger, Jordan C Weyer, Marion J Wood, H Shonna Yin, William T Zempsky, Emily Zimmerman, Benard P Dreyer, RECOVER-Pediatric Consortium

“…The data and biosamples will allow examination of mechanistic hypotheses and biomarkers, thus providing insights into potential therapeutic interventions.<h4>Clinical trials.gov identifier</h4>Clinical Trial Registration: http://www.clinicaltrials.gov. …”
Get full text

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors by Alfred Zippelius, Petra Herzig, Pratiksha Gulati, Christian Klein, Marta Trüb, Kirsten D Mertz, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Marina Natoli, Klas Hatje, Fabian Junker, Zhiwen Jiang, Iakov I Davydov, Markus Germann, Daniel Marbach, Adrian Zwick, Patrick Weber, Stefan Seeber, Lothar Tietze, Laura Codarri-Deak, Henry Kao

“…Background Next-generation cancer immunotherapies are designed to broaden the therapeutic repertoire by targeting new immune checkpoints including lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin and mucin-domain containing-3 (TIM-3). …”
Get full text

Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database by Yuwei Liu, Yuwei Liu, Xu Zhao, Xu Zhao, Xinrui Wang, Xinrui Wang, Qiang Zhou, Qiang Zhou

“…This study assessed ADRs associated with anti-fibrotic agents as reported in the World Health Organization (WHO) VigiAccess database and compared the adverse reaction characteristics of these agents for optimizing therapeutic strategies.MethodsA detailed search was conducted on ClinicalTrial.gov to identify phase 3 or 4 clinical trials involving hepatic anti-fibrotic agents. …”
Get full text